Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
CD40-independent NK-cell help promotes dendritic cell vaccine-induced T-cell immunity against endogenous B-cell lymphoma.
Int. J. Cancer 135, 2825-2833 (2014)
It is well established that an interplay between natural killer (NK) cells and dendritic cells (DCs) gives rise to their reciprocal activation and provides a Th1-biased cytokine milieu that fosters antitumor T-cell responses. Ex-vivo differentiated DCs transferred into mice strongly stimulate endogenous NK cells to produce IFN-γ and initiate a cascade that eventually leads to cytotoxic T-lymphocyte responses. We show that the ability of exogenous DCs to trigger this pathway obviates CD40 signaling and CD4(+) T-cell help and depends on a preceding maturation step. Importantly, this mechanism was also effective in endogenously arising tumors where IFN-γ production is compromised in contrast to transplantable tumors. In c-myc-transgenic mice developing spontaneous lymphomas, injection of unpulsed DCs caused NK-cell activation and induced CD8(+) T cells capable of recognizing the lymphoma cells. Animals treated with unpulsed DCs showed a survival benefit compared to untreated myc mice. Hence, tumor immunity induced by DC-based vaccines not only depends on specific antigens loaded on the DCs. Rather, DC vaccines generate broader immune responses, because endogenous DCs presenting tumor antigens may also become stimulated by NK cells that were activated by exogenous DCs. Thus, the DC/NK-cell/CTL axis may commonly have relevance for DC-based vaccination protocols in clinical settings.
Altmetric
Weitere Metriken?
Zusatzinfos bearbeiten
[➜Einloggen]
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Wissenschaftlicher Artikel
Schlagwörter
Ctl Response ; Dc Maturation ; Adaptive Antitumor Immunity ; Interferon-γ ; λ-myc Mouse; Antitumor Immunity; Nk Cells; In-vivo; Tumor; Responses; Antigen; Recruitment; Induction; Receptor; Therapy
ISSN (print) / ISBN
0020-7136
e-ISSN
1097-0215
Zeitschrift
International Journal of Cancer
Quellenangaben
Band: 135,
Heft: 12,
Seiten: 2825-2833
Verlag
Wiley
Verlagsort
Hoboken
Begutachtungsstatus
Peer reviewed
Institut(e)
Institute of Molecular Immunology (IMI)